By proceeding, you agree to our Terms of Use and Privacy Policy.
Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of unique, innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research.
25-27 January 2022
Validate Your Preclinical Hypothesis by Dissecting Solid Tumor Microenvironment, Predictive Biomarker, Safety & Clinical Efficacy Analysis through Next Gen Models & Bioinformatics The last 12 months witnessed the surge of exciting combination immuno-
Event Ended
Virtual
Paid
22-24 March 2022
The 3rd TLR & PRR-Targeted Therapies Summit is coming at a timely inflection point in this field.
USA
Boston
The STING & TLR-Targeting Therapies Summit is coming at a timely inflection point in this field.
26-28 April 2022
The 2nd Fc Receptor & IgG Targeted Therapies Summit is your definitive meeting for the most up-to-date clinical and commercial developments on pioneering strategies to modulate FcRs and harness their full therapeutic potential.
12-14 July 2022
From Leveraging Emerging Predictive Technologies to Engineering a Human-Physiologically Relevant Models – Deepen Our Understanding of Tumor Biology, Resistance Mechanisms & Dosing Strategy Following the success of KRAS, HER2, BCMA, drug developers ha
07-08 December 2022
With next generation of complex immuno-oncology candidates, preclinical and translational scientists in the IO space are in need for more predictive tumour models to improve clinical translatability, accelerating speed-to-clinic with confidence.
UK
London
24-26 January 2023
With 2023 on track to see further growth in the immuno-oncology field, the availability of tools that offers drug developers & researchers advantages that weren’t available to them even a few years ago is increasing rapidly.
San Francisco
18-20 April 2023
The pharmaceutical industry is currently focused on developing biologic drugs that target the FcRn receptor pathway to treat autoimmune diseases, with companies such as Argenx, Janssen, UCB and Immunovant competing to tackle myasthenia gravis. The 3r
25-27 April 2023
Welcome to the 5th Annual Cell Engager Summit! Tecytinib’s approval last year has strongly fuelled the mentality that this is the year of cell engager! Bispecifics have led the way and liquid tumors have been hit hard. Now Immunocore and others are s
18-20 July 2023
Welcome to the 3rd Tumor Myeloid-Directed Therapies SummitThe role of the myeloid compartment in tumor resistance is becoming clear. As the landscape of targets continues to grow, the potential to target and manipulate myeloid cells to relieve im